Patients characteristics
CRPA, Coma, carbapenem-resistant Acinetobacter
HAND INFECTION, OBESE, PSEUDOMONAS AERUGINOSA, COMA
A total of 347 patients were screened between January 2021 and 2022, and of them, 36 were excluded. Finally, the trial comprised 311 patients, of whom 152 were randomly assigned to the HD group and 159 to the LD group (Fig. Trial profilePolymyxin B was administered at a lower dose in 159 patients than in 152 patients who received a higher dose. All of them received a loading dose; the HD group received a loading dose of 2.14 (interquartile range [IQR] 2, 2.5) mg/kg and a maintenance dose of 2.14 (IQR 2, 2.5) mg/kg/day, and the LD group received a loading dose of 1.54 (IQR 1.41, 1.75) mg/kg and a maintenance dose of 1.54 (IQR 1.41, 1.75) mg/kg/day. The median age of both groups was 58, and the average acute physiology and chronic health assessment (APACHE II) score were 18.7 in the HD group and 18.4 in the LD group. TBWs ranged from 45 to 99 kg (68.5 [IQR 60, 75]) in 150 patients in the HD group, and 2 patients were extremely obese at 120 kg and 180 kg, respectively. On the other hand, TBWs ranged from 40 to 100 kg (65.0 [IQR 57.0, 71.0]) in 159 patients in the LD group. The two groups were similar in most baseline characteristics and severity but not in TBW (70.0 [IQR 60.0, 75.0] vs. 65.0 [IQR 57.0, 71.0]; Patient and infection characteristicsData are mean (SD), n (%), or median (IQR). HD: high dose. LD: low dose. BMI = body mass index. CRE = carbapenem-resistant Enterobacteriaceae. CRAB = carbapenem-resistant Acinetobacter baumannii. CRPA = carbapenem-resistant Pseudomonas aeruginosa. Scr: serum creatinine. GCS = Glasgow Coma Scale. APACHE = Acute Physiology and Chronic Health Evaluation. SOFA = Sequential Organ Failure Assessment. X = β-lactam / aminoglycosides / cephalosporin / quinolone / oxazolidinone / minocycline / fosfomycin